Products Meningococcal ACWY Polysaccharide Vaccine + MenACWY CRM (19 to 55 years) + Meningococcal ACWY Conjugate Vaccine + Novartis MenACWY Vaccine (56 to 65 Years)
Meningococcal ACWY Polysaccharide Vaccine + MenACWY CRM (19 to 55 years) + Meningococcal ACWY Conjugate Vaccine + Novartis MenACWY Vaccine (56 to 65 Years) Phase 3 Completed 📈 Rising Meningococcal Meningitis, Meningococcal Infections
May 1, 2007 → Feb 1, 2008
About Meningococcal ACWY Polysaccharide Vaccine + MenACWY CRM (19 to 55 years) + Meningococcal ACWY Conjugate Vaccine + Novartis MenACWY Vaccine (56 to 65 Years) Meningococcal ACWY Polysaccharide Vaccine + MenACWY CRM (19 to 55 years) + Meningococcal ACWY Conjugate Vaccine + Novartis MenACWY Vaccine (56 to 65 Years) is a phase 3 stage product being developed by Novartis for Meningococcal Meningitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00474487. Target conditions include Meningococcal Meningitis, Meningococcal Infections.
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT00474487 Phase 3 Completed May 1, 2007 Feb 1, 2008 Meningococcal Meningitis
Product Company Stage Hype Score RotaTeq® + NeisVac-C® Merck Phase 3 Meningococcal C conjugate vaccine Novartis Approved Meningococcal (group B) multicomponent recombinant adsorbed vaccine. + Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV) Novartis Phase 2 Meningococcal ACWY-CRM conjugate vaccine + Meningococcal ACWY-PS polysaccharide vaccine Novartis Phase 3 1a - rMenB+OMV NZ and routine vaccines + 1b - rMenB+OMV NZ and routine vaccines + 2a - Routine and rMenB+OMV NZ vaccines + 2b - rMenB+OMV NZ and routine vaccines + 3a - rMenB+OMV NZ and routine vaccines + 3b - 1 dose of rMenB+OMV NZ plus routine infant vaccinations + 4a- rMenB+OMV NZ and routine vaccines + 4b - rMenB+OMV NZ and routine vaccines Novartis Phase 3 MenACWY-CRM Novartis Pre-clinical Meningococcal C conjugate vaccine Novartis Approved Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine + MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine Novartis Approved rMenB + rMenB+OMV NZ Novartis Phase 2 Typhoid Vi Polysaccharide Vaccine + Yellow Fever Vaccine + Japanese Encephalitis Vaccine + Rabies Vaccine + MenACWY-CRM Vaccine Novartis Phase 3 rMenB+OMV NZ Novartis Phase 3 Meningococcal ACWY Conjugate Vaccine + DTaP-IPV-HBV + Hib + Rotavirus + Pneumococcal 7-valent Conjugate Vaccine + HAV + MMR-V + DTaP Novartis Phase 3 Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + Meningococcal (group B) multicomponent recombinant adsorbed vaccine + Tdap Novartis Phase 2 MenACWY-CRM Novartis Phase 3 rMenB + rMenB+OMV Novartis Phase 2 MenC-CRM LIQ + MenC-CRM ROS + MenC-CRM EMV Novartis Phase 2 Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV. + Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV. + Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine. + Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV. Novartis Phase 2 MenABCWY+OMV + MenABCWY+¼OMV + Placebo Novartis Phase 2 Novartis MenACWY-CRM + Saline Placebo Novartis Phase 3 rMenB+OMV NZ + Placebo Novartis Phase 2/3
Other Products from Novartis